N

Nexstim Oyj
OMXH:NXTMH

Watchlist Manager
Nexstim Oyj
OMXH:NXTMH
Watchlist
Price: 5.08 EUR -1.55% Market Closed
Market Cap: 34.4m EUR
Have any thoughts about
Nexstim Oyj?
Write Note

Nexstim Oyj
Depreciation & Amortization

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Nexstim Oyj
Depreciation & Amortization Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Depreciation & Amortization CAGR 3Y CAGR 5Y CAGR 10Y
N
Nexstim Oyj
OMXH:NXTMH
Depreciation & Amortization
-€755.3k
CAGR 3-Years
-29%
CAGR 5-Years
-10%
CAGR 10-Years
N/A
R
Revenio Group Oyj
OMXH:REG1V
Depreciation & Amortization
-€5.1m
CAGR 3-Years
-22%
CAGR 5-Years
-26%
CAGR 10-Years
-35%
M
Modulight Oyj
OMXH:MODU
Depreciation & Amortization
-€3.6m
CAGR 3-Years
-50%
CAGR 5-Years
-36%
CAGR 10-Years
N/A
B
Bioretec Oy
OMXH:BRETEC
Depreciation & Amortization
-€120.5k
CAGR 3-Years
4%
CAGR 5-Years
-27%
CAGR 10-Years
N/A
O
Optomed Oyj
OMXH:OPTOMED
Depreciation & Amortization
-€2.2m
CAGR 3-Years
0%
CAGR 5-Years
-4%
CAGR 10-Years
N/A
B
Biohit Oyj
OMXH:BIOBV
Depreciation & Amortization
-€364k
CAGR 3-Years
43%
CAGR 5-Years
29%
CAGR 10-Years
N/A
No Stocks Found

Nexstim Oyj
Glance View

Market Cap
34.4m EUR
Industry
Health Care

Nexstim Oyj engages in the provision of medical technology products. The company is headquartered in Helsinki, Etela-Suomen and currently employs 37 full-time employees. The company went IPO on 2014-11-14. The company is focused on improving rehabilitation for stroke patients through the use of noninvasive brain stimulation. Its offering comprises: a diagnostic tool for brain surgery planning, Navigated Brain Stimulation (NBS) System, which comprises navigated transcranial magnetic stimulation (nTMS) device for presurgical mapping (PSM) of the motor and speech cortices; and a device for stroke therapy called Navigated Brain Therapy (NBT) System, which focuses stimulation on targeted locations in the brain in order to enhance rehabilitation process. The NBT System targets upper limb motor disability and is under Phase III pivotal clinical trial study at rehabilitation sites in the United States. The Company’s systems are used in over 100 facilities in research, therapy and neurosurgical planning purposes. Nexstim Oyj has two subsidiaries: Nexstim Inc and Nexstim Germany GmbH.

NXTMH Intrinsic Value
4.42 EUR
Overvaluation 13%
Intrinsic Value
Price
N

See Also

What is Nexstim Oyj's Depreciation & Amortization?
Depreciation & Amortization
-755.3k EUR

Based on the financial report for Jun 30, 2024, Nexstim Oyj's Depreciation & Amortization amounts to -755.3k EUR.

What is Nexstim Oyj's Depreciation & Amortization growth rate?
Depreciation & Amortization CAGR 5Y
-10%

Over the last year, the Depreciation & Amortization growth was -29%. The average annual Depreciation & Amortization growth rates for Nexstim Oyj have been -29% over the past three years , -10% over the past five years .

Back to Top